Intaza 150 150 mg/Vial Powder for suspension for injection
PDF Leaflet Revision Date: 11 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelodysplastic syndromes.
Dosage (summary)
75 mg/mu00b2 subcutaneously daily for 7 days every 4 weeks; may increase to 100 mg/mu00b2 if no response.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential reproductive toxicity.
Contraindications
- Hypersensitivity to azacitidine
- Advanced malignant hepatic tumours
- Severe renal impairment
- Pregnancy and lactation
- Children under 18 years
Common side effects
- Anaemia
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
Counselling Points
- Monitor for signs of bleeding
- Report febrile episodes
- Use effective contraception during treatment
Serious warnings
- Haematological toxicity
- Risk of necrotising fasciitis
- Cardiac events in patients with history of cardiovascular disease
Important Disclaimer
The Intaza 150 150 mg/Vial Powder for suspension for injection professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
